The effects of exendin-4 treatment on graft failure: an animal study using a novel re-vascularized minimal human islet transplant model

PloS One
Afaf SahraouiHanne Scholz

Abstract

Islet transplantation has become a viable clinical treatment, but is still compromised by long-term graft failure. Exendin-4, a glucagon-like peptide 1 receptor agonist, has in clinical studies been shown to improve insulin secretion in islet transplanted patients. However, little is known about the effect of exendin-4 on other metabolic parameters. We therefore aimed to determine what influence exendin-4 would have on revascularized minimal human islet grafts in a state of graft failure in terms of glucose metabolism, body weight, lipid levels and graft survival. Introducing the bilateral, subcapsular islet transplantation model, we first transplanted diabetic mice with a murine graft under the left kidney capsule sufficient to restore normoglycemia. After a convalescent period, we performed a second transplantation under the right kidney capsule with a minimal human islet graft and allowed for a second recovery. We then performed a left-sided nephrectomy, and immediately started treatment with exendin-4 with a low (20μg/kg/day) or high (200μg/kg/day) dose, or saline subcutaneously twice daily for 15 days. Blood was sampled, blood glucose and body weight monitored. The transplanted human islet grafts were collected at study en...Continue Reading

References

Apr 25, 2001·Metabolism: Clinical and Experimental·D G ParkesA Young
Nov 1, 2002·The Journal of Biological Chemistry·Yazhou LiDaniel J Drucker
Jun 16, 2004·International Journal of Obesity and Related Metabolic Disorders : Journal of the International Association for the Study of Obesity·R A PittnerA A Young
Jun 20, 2006·Biochemical and Biophysical Research Communications·Junqin ChenAnath Shalev
Dec 28, 2006·Proceedings of the National Academy of Sciences of the United States of America·Takuya SugiyamaSeung K Kim
Nov 8, 2008·Journal of Visualized Experiments : JoVE·Gregory L SzotJeffrey A Bluestone
Jun 2, 2011·Transplant International : Official Journal of the European Society for Organ Transplantation·Lei TianZhiguang Guo
Jan 19, 2012·Endocrinology·Kalpana VelmuruganSubbiah Pugazhenthi
Feb 18, 2012·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Wei Gao, William J Jusko
Mar 1, 2012·Journal of Pharmacy & Pharmaceutical Sciences : a Publication of the Canadian Society for Pharmaceutical Sciences, Société Canadienne Des Sciences Pharmaceutiques·Shekoufeh NikfarPooneh Salari
Jun 23, 2012·Diabetes Care·Franca B BartonA M James Shapiro
Sep 18, 2012·Metabolism: Clinical and Experimental·Jian LuoZhiguang Guo
Jan 1, 2014·Progress in Molecular Biology and Translational Science·Prashant NadkarniGeorge G Holz
Jun 3, 2014·International Journal of Endocrinology·Mazhar A KanakBashoo Naziruddin

❮ Previous
Next ❯

Methods Mentioned

BETA
sedation
ELISA

Software Mentioned

Definiens
GraphPad Prism
ZEN lite
Image J
Metafer

Related Concepts

Related Feeds

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Cardiovascular Biology of GLP-1

Glucagon-like peptide 1 (GLP-1) plays a role in glucose metabolism, energy homeostasis, and inflammation suppression. GLP-1 receptor signaling has been shown to impact cardiovascular function. This feed focuses on the role of GLP-1 and GLP-1 receptor agonists on cardiovascular biology.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis